ROKIT Healthcare, an artificial intelligence (AI)-based organ regeneration platform corporations, said on the 11th that last year's sales on a consolidation basis were 26.2 billion won, up 100% from a year earlier.
Operating profit last year was 600 million won, turning to the black from an operating loss of 5.5 billion won a year earlier. However, with valuation losses on convertible bonds reflected, net profit recorded a deficit.
The company said the figures were "accounting numbers reflecting valuation losses on convertible bonds, etc.," adding, "It is only an accounting valuation loss, and there is no actual cash outflow." It added, "Once the convertible bond conversions are completed, capital will be strengthened and the financial structure will become even more solid."
In the fourth quarter last year, sales were 9.58 billion won and operating profit was 750 million won.
A ROKIT Healthcare official said, "2025 was the first year in which we achieved both top-line growth and internal improvement, laying the global fundamentals for 'cartilage regeneration,' 'kidney regeneration,' and 'anti-aging'," adding, "This year, we will accelerate growth based on that."